Mirikizumab Improves Quality of Life in Patients With Moderately-to-Severely Active Ulcerative Colitis: Results From the Phase 3 LUCENT-1 Induction and LUCENT-2 Maintenance Studies.
Bruce E SandsBrian G FeaganTheresa Hunter GibbleKristina A TraxlerNathan MorrisWilliam J EastmanStefan SchreiberVipul JairathMillie D LongAlessandro ArmuzziPublished in: Crohn's & colitis 360 (2023)
LUCENT-1: NCT03518086; LUCENT-2: NCT03524092.
Keyphrases